AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05871918
Drug: TCbHP VS ddEC-THP
RxNorm normalized name: THP-Adm
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.
Trial: NCT04868253
Drug: EMB-01
RxNorm normalized name: EMB-01
DrugBank: EMB-01 (DB16091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).
Trial: NCT02568943
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat (PAN \[LBH589\]) is an orally administered pan-deacetylase inhibitor (DACi) belonging to a structurally novel class of compounds deregulating cell proliferation and survival mechanisms of cancer cells.
Trial: NCT05508906
Drug: OP-1250
RxNorm normalized name: OP-1
DrugBank: Eptotermin alfa (DB11631)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: OP-1250 is a small molecule and a CERAN being developed for the treatment of patients with advanced or metastatic ER+ and HER2- breast cancer.
Trial: NCT05508906
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All subjects in Treatment Group 1 will receive OP-1250 in combination with ribociclib.
Trial: NCT05508906
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects in Treatment Group 2 will receive OP-1250 in combination with alpelisib.
Trial: NCT05508906
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects in Treatment Group 3 will receive OP-1250 in combination with everolimus.
Trial: NCT05150587
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin tablets
Trial: NCT04978259
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous remdesivir during hospital stay up to 10 days in addition to standard care.
Trial: NCT05825391
Drug: Adjustment of Antiplatelet Drugs
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The maximum platelet aggregation rate induced by arachidonic acid (AA-MPA)≥20%, give aspirin 200mg qd. The maximum platelet aggregation rate induced by adenosine diphosphatase (ADP-MPA)≥36.4% for flow diversion, give ticagrelor 60mg bid. ADP-MPA≥42.9% for stent-assisted coil embolization，give ticagrelor 60mg bid. ADP-MPA\<20%, give clopidogrel 37.5mg qd. The timing of drug adjustment should be at least 1 day before stent implantation, and the LTA testing should be performed again 48 hours after the drug adjustment. For patients whose ADP-MPA does not reach the normal range, a second antiplatelet drug adjustment should be performed: ticagrelor overdose: reduce to 45mg bid; ticagrelor resistance, increase to 90 mg bid.
Trial: NCT05469412
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard management combined with pharmacological intervention (oral midazolam 0.5 mg/kg) administered at least 30 min before surgery (maximum 20mg).
Trial: NCT04741490
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1antibodies，200mg ivgtt Q3W
Trial: NCT00414089
Drug: 90Y-ibritumomab tiuxetan (Zevalin)
RxNorm normalized name: ibritumomab tiuxetan (90Y)
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01122004
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05098327
Drug: Pioglitazone 30 mg
RxNorm normalized name: pioglitazone 30 MG
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pioglitazone 30 mg dose 1 tab daily will be given for 12 weeks
Trial: NCT06138275
Drug: Elranatamab
RxNorm normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous (under the skin) injection
Trial: NCT06382285
Drug: Continues peripheral block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ropivacaine (Naropin) 0.2% according to a protocol 8-10 cc per hour up to 24 hours after surgery
Trial: NCT05203224
Drug: Dornase Alfa
RxNorm normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Dornase alfa
Trial: NCT04811118
Drug: Docetaxel for Injection (Albumin-bound)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel for Injection (Albumin-bound) by intravenous infusion
Trial: NCT04811118
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taxotere
Trial: NCT05154240
Drug: INS018_055
RxNorm normalized name: INS018_055
DrugBank: INS018_055 (DB18083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INS018_055 is a small molecule compound. INS018_055 has good solubility in water and was chemically and physically stable at different temperatures.
Trial: NCT06475287
Drug: HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The combination therapy of HAIC with TQB2450 and Anlotinib was administered to enrolled patients in no particular order. Patients received routine hepatic artery catheterization via femoral artery puncture, followed by routine hepatic artery catheterization and infusion chemotherapy with 5% sodium bicarbonate 150ml + liposomal mitoxantrone (10mg) for 2-4 hours + Raltitrexed (2mg/m2) for 2-4 hours, every three weeks for at least two cycles. Systemic treatment was given every 21 days, with a fixed dose of 1200mg of TQB2450 injection on the first day of each systemic treatment cycle (1-7 days after HAIC treatment), administered intravenously over 60 minutes initially, followed by 30 minutes if tolerated. Anlotinib was administered orally once daily at a dose of 10mg, with a two-week break every three weeks. Treatment continued until unacceptable toxicity or loss of clinical benefit (as assessed by the investigator based on imaging, biochemical indicators, and patient clinical status).
Trial: NCT06158828
Drug: Rabbit Anti thymocyte globulin
DrugBank: Rabbit (DB10415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rATG is administered intravenously over 6-18 hours for a total of 2 to 3 doses. The daily dose is based on body weight and lymphocyte count.
Trial: NCT06158828
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan is administered intravenously either Q6H or Q24H, with a recommended target Busulfan AUC of 70-90 mg\*h/L.
Trial: NCT06158828
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine is administered intravenously at a dose of 40 mg/m\^2/dose once daily for 4 days.
Trial: NCT06158828
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thiotepa is administered intravenously at a dose of 5 mg/kg/dose Q12H for 2 doses.
Trial: NCT06158828
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan is administered intravenously at a dose of 70 mg/m\^2/dose once daily for 2 days.
Trial: NCT06158828
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If suboptimal collection of stem cells is predicted, plerixafor may be administered at a dose of 0.24 mg/kg subcutaneous injection once (maximum 40mg/dose). For patients with renal impairment, plerixafor will be administered at a dose of 0.16 mg/kg subcutaneous injection (maximum 27 mg/day).
Trial: NCT05238363
Drug: HLX07
RxNorm normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX07 1500mg ivgtt Q3W
Trial: NCT04877093
Drug: Clonidine Pill
RxNorm normalized name: clonidine Pill
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study will use a flexible-dose adjustment schedule to identify the minimum dose needed to alleviate symptoms while also ensuring acceptable adverse effects. In other words, all subjects will start at the minimum dose (0.1 mg/night). Near the end of every week, each subject will be assessed for symptom alleviation and adverse events by asking the patient two questions from the CAPS-5 (questions B2 and E6. At baseline, each patient will have scored a ≥3 on each of these questions. If one or both scores remain at ≥3 and if any reported adverse events are marked acceptable by both the clinician and subject, then the dosage for the following week will be increased one level according to the titration chart. However, if both scores for these questions are ≤2 and any current adverse events are acceptable, then the dosage will remain the same. Finally, if any adverse events are deemed unacceptable, the clonidine dosage will be reduced to the lowest acceptable daily dosage.
Trial: NCT06298968
Drug: combined therapy using gemcitabine and cisplatin chemotherapy, Lenvatinib and Adebrelimab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (1000mg/m²) and cisplatin (25mg/m²) on day1 and 8 every 3 weeks, with a total of 6 cycles.~Lenvatinib 8 mg once daily (QD) oral dosing, continuous use for 2 years. Adebrelimab 1200mg intravenously every 3 weeks, continuous use for 2 years.
Trial: NCT00960921
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
Trial: NCT01308047
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of 15mg by a slow injection rate of 1 ml/s
Trial: NCT05582096
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04833296
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all patients will receive interscalene block using same volume of ropivacaine but in different concentrations
Trial: NCT05264142
Drug: Voriconazole 200mg
RxNorm normalized name: VORICONAZOLE 200MG TAB
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.
Trial: NCT05264142
Drug: FluvoxaMINE 50 Mg Oral Tablet
RxNorm normalized name: fluvoxaMINE 50 mg oral tablet
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.
Trial: NCT05264142
Drug: Omeprazole 10 MG Oral Tablet
RxNorm normalized name: omeprazole 10 MG Oral Tablet
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.
Trial: NCT04727476
Drug: Lisdexamfetamine
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prescription of lisdexamfetamine sometime during til period from 1 April 2013 to 5 November 2019.
Trial: NCT05591170
Drug: Cholecalciferol 120 000 IU
RxNorm normalized name: cholecalciferol 120 UNT
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single, oral administration of high dose of vitamin D
Trial: NCT04732247
Drug: Oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
Trial: NCT04673877
Drug: Systemic IV Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g of vancomycin will be delivered intravenously over a period of one hour prior to tourniquet inflation.
Trial: NCT04673877
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg diluted in 50 cc normal saline of injection into superficial vein in the hand, wrist or forearm
Trial: NCT00866983
Drug: sildenafil (Revatio) 20 mg TID
RxNorm normalized name: sildenafil 20 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
Trial: NCT06187597
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Patients received S-1 administration, 70mg/m2 per day, orally on days 1 to 14 and 29 to 42 during radiotherapy.
Trial: NCT06187597
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received toripalimab 240 mg every 3 weeks for up to 16 cycles.
Trial: NCT05277090
Drug: 2L of polyethyleneglycol
RxNorm normalized name: Oil of peppermint
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2L of polyethyleneglycol
Trial: NCT06291155
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will be receive 100 mg/daily doses of Canagliflozin (INVOKANA) for 6 months. Canagliflozin is a Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Trial: NCT05946707
Drug: liberal oxygen supply
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen supply will be maximized to 100% at the beginning of OLV
Trial: NCT05307627
Drug: low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LDN doses \<20 mg/day
Trial: NCT06514313
Drug: Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine
RxNorm normalized name: irinotecan hydrochloride liposome
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion , 4 cycles.
Trial: NCT06514313
Drug: Temozolomide+Irinotecan+Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Q3W, 4 cycles
Trial: NCT06142617
Drug: Pembrolizumab, pemetrexed, platinum
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Four cycles of platinum and pemetrexed in combination with pembrolizumab will be administered as first line therapy and up to 31 cycles pemetrexed and pembrolizumab maintenance therapy every 3 weeks.
Trial: NCT06142617
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib will be the sequential treatment strategy at progression until resistance develops.
Trial: NCT06510010
Drug: Oxaliplatin With S-1 (SOX) Combined H. Pylori Eradication (Amoxicillin + clarithromycin + omeprazole + colloidal bismuth subcitrate)
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin With S-1 (SOX) regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle.~H. pylori eradication regimen:~H. pylori eradication was performed using a quadruple regimen for 14 d. Omeprazole 20 mg bid+Colloidal bismuth subcitrate 220mg bid+Amoxicillin 1g bid+Clarithromycin 500mg bid.
Trial: NCT06510010
Drug: Oxaliplatin With S-1 （SOX）
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin With S-1 （SOX） regimen:~S-1: 40mg/m2, oral, bid, D1-14, one cycle every 3 weeks; Oxaliplatin: 130 mg/m2, IV, qd, D1, every 3 weeks for one cycle.
Trial: NCT04031573
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 2.5 to 5 mg to achieve a target heart rate between 80 and 94 bpm
Trial: NCT04031573
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 5 to 7.5 mg to achieve a target heart rate between 80 and 94
Trial: NCT04661475
Drug: Dexmedetomidine Injection [Precedex]
RxNorm normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ECT and anaesthetic treatment protocols will be determined by the local ECT services. ECT being given twice a week. The anesthetic induction agent of choice will usually be propofol, with thiopental permissible as an alternative. For safety reasons, any drug contraindicated to be given with DEX will be avoided. Especially the once known to decrease arterial pressure and heart rate excessively. Oral psychotropic medication to be continued by the patient's treating clinical team will remain unchanged where possible for at least the first 4 ECT treatments, and ideally until end of ECT. Eligible subjects will be allocated randomly to receive either 0.5µg/kg dexmedetomidine add on (diluted to 10 ml with 0.9% saline) at a steady rate of 1 ml/min, for 10 min.Participants in the two groups will receive DEX or Saline adjunct thrice weekly for 3 weeks.
Trial: NCT06584162
Drug: Vedolizumab Injection
RxNorm normalized name: vedolizumab Injection
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Based on therapeutic drug monitoring, patients could be de-escalated based on a pharmacokinetic model:~Dosing interval Trough Target 20 mg/L~Adjust dosing interval to:~2 weeks \< 33 mg/L 2 weeks 2 weeks 33 - 46 mg/L 3 weeks 2 weeks ≥ 46 mg/L 4 weeks 3 weeks \< 20 mg/L 2 weeks 3 weeks 20 - 29 mg/L 3 weeks 3 weeks ≥ 29 mg/L 4 weeks 4 weeks \< 13 mg/L 2 weeks 4 weeks 13 - 20 mg/L 3 weeks Version number: 6.1, 24-06-2024 22 of 44 4 weeks ≥ 20 mg/L 4 week
Trial: NCT05710198
Drug: Citicoline eye drops 2%
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drops containing Citicoline 2%
Trial: NCT04703257
Drug: Metamizole
RxNorm normalized name: Metamizole
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days patients will be instructed to take 1000 mg paracetamol orally four times a day for four days. .
Trial: NCT04853147
Drug: palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,
Trial: NCT04853147
Drug: palonosetron, dexamethasone, and 0.9% NaCl
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,
Trial: NCT06546098
Drug: Molgramostim nebulizer solution
RxNorm normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for inhalation
Trial: NCT06072963
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The medication is available in 3, 7, and 14-mg tablets for oral use. Participants will be instructed to start with an initiating dose of 3 mg once daily. If they do not experience adverse events (nausea, vomiting, and abdominal pain) then the dose will be titrated to 7 mg once daily after 30 days. Again, if the participant does not experience adverse events, the dose will be further titrated after 30 days to 14 mg once daily. This does will continue until the end of the study, at 12 months.
Trial: NCT06072963
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study will use the ViaNase; Kurve Technology intranasal device to administer insulin intra-nasally. This device has been used in other studies of persons with AD and has shown insulin penetration into the brain via CSF studies. Through sniffing, the medication crosses the blood-brain barrier (BBB) at the top of the nasal cavity. Participants will be instructed to press a switch that will turn on the device, engaging a pump that releases a nebulized stream of insulin through a nose piece into a nostril for 20 seconds (the device includes an electronic timer), after which the device switches off. The process is then repeated in the other nostril. The investigators decided on administration of 20IU of INI twice per day as the literature suggests this as the optimal dosage.
Trial: NCT00002093
Drug: Daunorubicin (liposomal)
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002093
Drug: Bleomycin sulfate
RxNorm normalized name: Bleomycin Sulfate
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002093
Drug: Vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no